Melanocortin receptor ligands

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9850280
SERIAL NO

15587426

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to compounds according to formula,

description='In-line Formulae' end='lead'(R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1,description='In-line Formulae' end='tail'

and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IPSEN PHARMA S A S65 QUAI GEORGES GORSE BOULOGNE-BILLANCOURT 92100

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dong, Zheng Xin Holliston, US 114 936
Moreau, Jacques-Pierre Upton, US 54 826

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 26, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 26, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00